CRISPR Therapeutics AG (CRSP) Total Debt (2026)

CRISPR Therapeutics AG (CRSP) posted Total Debt of $585.5 million for Q1 2026.

CRISPR Therapeutics AG (CRSP) Total Debt (2026) Analysis & Trends

CRISPR Therapeutics AG has reported Total Debt for 1 years, with the latest figure at $585.5 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.07 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.34 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 546.77 Mn
10 CRISPR Therapeutics AG 5.18 Bn 5.18 Bn - 586.20 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 586.20 Mn
Mar 31, 2026 585.47 Mn